Labcorp Holdings (LH) Expands Cancer And Liver Testing, Is It Fully Priced?
Labcorp Holdings (LH) is in focus after peer reviewed studies highlighted its Metabolic Vulnerability Index and NIS2+ blood test for liver disease risk, alongside the nationwide, Medicare covered rollout of its RNA based ColoSense colorectal screening kit. See our latest analysis for Labcorp Holdings. Those product updates sit alongside steady share price momentum, with Labcorp Holdings posting a 1-month share price…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
